CTLT Catalent, Inc: Net earnings per share for the last four quarters

Public company logo of Catalent Inc. (CTLT)

Catalent, Inc. (CTLT) generates revenue through the contract manufacturing of complex biologics and vaccines for global tech giants. The historical EPS YoY TTM delta clearly demonstrates profit dynamics, where the -412.00 level indicates the state of the yield parameter. Revenues are moderately dependent on new drug launch cycles, while regulatory pressure and the deal with Novo Holdings create additional operational risks.

CTLT (Catalent) Earnings per share for the last twelve months history from 02/11/2024 to 02/20/2024

Catalent, Inc - analytical breakdowns and key metrics (CTLT)

- price and consensus price forecast:
Fundamental valuation:Catalent (CTLT)
Manufactured product of Catalent Pharma Solutions

This indicator measures the rolling year-over-year change in earnings per share, reflecting the growth rates of the business's real income. For Catalent, Inc. (CTLT), this metric is driven by the production efficiency of scarce obesity therapy drugs. By analyzing the YoY growth in net income per share over the last 12 months, investors can assess the current operational profitability. The current trend confirms the fundamental stability of Catalent, Inc. (CTLT) ahead of its acquisition. It is critical to consider the risk of false market impulses when breaking out of consolidation.